Price
$72.97-53.12%Social Signal Score
Analyst Ratings
32 analysts52-week range
- Last close
- $72.97
- Off 52w high
- -53.5%
- 200-day average
- $106.60
- vs 200-day
- -31.5%
Revenue
$2.39B+87.24%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kristin C. Peck
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 14,500
- Beta
- 0.68
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 4.70
Financials
Revenue
$2.39B+87.2%Net Income
$591.00M+283.8%EBITDA
$910.00M+171.6%Free Cash Flow
$717.00M+217.3%EPS (diluted)
$1.44+364.5%Shares Outstanding (diluted)
411.60M-17.1%Operating Expenses
$756.00MCash & Debt
$1.53BReturn of Capital
$719.00MRevenue by Segment (annual)
$9.26BDividend per Share
$0.53Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $9.47B | $2.67B | $6.03 |
| 2024 | $9.26B | $2.49B | $5.47 |
| 2023 | $8.54B | $2.34B | $5.08 |
| 2022 | $8.08B | $2.11B | $4.51 |
| 2021 | $7.78B | $2.04B | $4.29 |
| 2020 | $6.67B | $1.64B | $3.44 |
| 2019 | $6.26B | $1.50B | $3.14 |
| 2018 | $5.83B | $1.43B | $2.96 |
| 2017 | $5.31B | $864.00M | $1.76 |
| 2016 | $4.89B | $821.00M | $1.66 |
| 2015 | $4.76B | $339.00M | $0.68 |
| 2014 | $4.79B | $583.00M | $1.16 |
| 2013 | $4.56B | $504.00M | $1.01 |
| 2012 | $4.34B | $436.00M | $0.87 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ZTS's reported EPS growth of 16.1% a year over 13 years.
- EPS in 5 years
- $12.72
- Implied price
- $267.02
- Return from $79.11
- 27.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $132.76 — today's price is already 40.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 15 | 18 | 21 | 24 | 27 |
|---|---|---|---|---|---|
| 6.1% | 9.0% | 13.0% | 16.6% | 19.7% | 22.6% |
| 11.1% | 14.1% | 18.3% | 22.1% | 25.4% | 28.3% |
| 16.1% | 19.2% | 23.7% | 27.5% | 31.0% | 34.1% |
| 21.1% | 24.4% | 29.0% | 33.0% | 36.6% | 39.9% |
| 26.1% | 29.5% | 34.3% | 38.5% | 42.3% | 45.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70-0.46%Social Signal Score
Mentions (59)
- Newsseekingalpha.com·6d ago·Positive
Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsbusinesswire.com·11d ago·Positive
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.
View source ↗ - Newszacks.com·13d ago·Neutral
ZTS Q3 Earnings Call Highlights Competitive Pressures and Outlook Zoetis beats Q3 earnings estimates despite revenue weakness, as competitive pressures, targeted promotions and product innovation shape its cautious 2027 outlook.
View source ↗ - Newsmarketbeat.com·14d ago·Negative
What Zoetis (ZTS) Said on Its Q3 Earnings Call Zoetis NYSE: ZTS reported lower third-quarter revenue as competition and weaker veterinary visits pressured its companion animal business, while livestock and diagnostics provided growth. The animal health company narrowed its full-year revenue outlook to the high end of its previous range and raised its adjusted earnings guidance.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Zoetis: Quality Company Trading Cheap Zoetis Inc., formerly Pfizer's veterinary arm, is a global leader in animal pharmaceuticals and diagnostics. ZTS generates most revenue from companion animal products, with approximately 30% from livestock healthcare solutions. We review why the stock has done so poorly and tell you why we went long.
View source ↗ - News (RSS)seekingalpha·16d ago·Neutral
Zoetis Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Zoetis Inc. (ZTS) Q3 2026 Earnings Call Transcript Zoetis Inc. ( ZTS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Mathieu Aussermeier Kristin Peck - CEO & Director James Saccaro - Executive VP, CFO & COO Conference Call Participants Christopher Schott - JPMorgan Chase & Co, Research Division David Westenberg - Piper Sandler & Co., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Brandon Vazquez - William Blair & Company L…
View source ↗ - News (RSS)fool·16d ago·Neutral
Zoetis: 3 Key Takeaways for Long-Term Investors Fast lifecycle approvals, such as Simparica Duo, are how Zoetis plans to extend its core franchises beyond today's pressured pet care market.
View source ↗ - Newsfool.com·16d ago·Positive
Zoetis: 3 Key Takeaways for Long-Term Investors Zoetis's organic operational revenue fell 1% in the third quarter. Global livestock revenue rose 7% to $797 million.
View source ↗ - Newszacks.com·17d ago·Neutral
ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up Zoetis beats third-quarter earnings and revenue estimates. Livestock sales growth partially offsets weakness in companion animal products.
View source ↗ - Newsreuters.com·17d ago·Neutral
Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall
View source ↗ - News (RSS)zerohedge·17d ago·Neutral
…n (9:10am) and Logan (7:00pm). Banxico decides at 2pm; BoC Governor Macklem speaks to the Senate at 10:30am. Notable earnings before the open include ConocoPhillips, Zoetis, Cigna, Duke and Southern; after the close, Airbnb, DraftKings, Cloudflare, Axon and Lumentum.Market SnapshotTop Overnight NewsGetting data centers built is “going to be harder” after the midterm elections, said Meta Platforms President Dina Powell McCormick—but perhaps not as hard as it now appears. WSJMicron Technology Inc.…
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Zoetis: Near-Term Expectations More Achievable, Long Growth Runway Undervalued Zoetis is emerging from a period of underperformance, with market expectations for Q3 and Q4 set notably low. Consensus and management guidance anticipate revenue and EPS declines, but these expectations appear beatable given ZTS's diversified growth levers. Long-term growth drivers include expanding parasite prevention, resilient livestock sales, and a nascent but promising diagnostics business.
View source ↗ - Newszacks.com·19d ago·Neutral
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect ZTS heads into Q3 earnings with international growth, livestock strength and demand for key companion animal products offsetting U.S. market challenges.
View source ↗ - Newszacks.com·24d ago·Neutral
Zoetis (ZTS) Ascends While Market Falls: Some Facts to Note In the most recent trading session, Zoetis (ZTS) closed at $78.8, indicating a +1.29% shift from the previous trading day.
View source ↗ - Newszacks.com·30d ago·Neutral
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note In the latest trading session, Zoetis (ZTS) closed at $81.03, marking a -1.18% move from the previous day.
View source ↗ - Newszacks.com·32d ago·Positive
ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet? Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.
View source ↗ - News (RSS)seekingalpha·32d ago·Negative
Zoetis: Weakening Fundamentals Overshadow The Discount
View source ↗ - News (RSS)investing·33d ago·Neutral
FDA approves Zoetis’ Convenia RTU for canine skin infections
View source ↗ - Newsbusinesswire.com·33d ago·Neutral
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections.
View source ↗ - News (RSS)investing·33d ago·Neutral
Why is Zoetis stock sliding today?
View source ↗ - News (Marketaux)gurufocus.com·37d ago·Positive
Zoetis Inc (ZTS) Stock Up 4.2% and Still Undervalued -- GF Score: 71/100 On October 15, 2026, Zoetis <em[+196 characters]
View source ↗ - News (RSS)investing·40d ago·Neutral
Zoetis appoints Iris Knobloch to board of directors
View source ↗ - Newszacks.com·44d ago·Positive
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know In the most recent trading session, Zoetis (ZTS) closed at $74.81, indicating a +2.37% shift from the previous trading day.
View source ↗ - Newsbusinesswire.com·45d ago·Negative
Zoetis Declares Fourth Quarter 2026 Dividend PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company's common stock as of the close of business on Friday, October 30, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurtur…
View source ↗ - Newszacks.com·52d ago·Neutral
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why Zoetis (ZTS) reached $69.1 at the closing of the latest trading day, reflecting a -1.05% change compared to its last close.
View source ↗ - News (RSS)seekingalpha·53d ago·Neutral
Zoetis: Priced For The Worst, Worth Buying
View source ↗ - Newsseekingalpha.com·53d ago·Neutral
Zoetis: Priced For The Worst, Worth Buying Zoetis Inc. (ZTS) has fallen 71% from its 2021 peak, now trading at 2017 levels, as pricing power eroded and pet medicine volumes declined. Despite near-term headwinds, Zoetis maintains industry-leading margins and is positioned to weather price wars better than rivals due to its product mix and scale. Patent expiries for Apoquel and Simparica in 2030/2032 are key risks, but a robust pipeline of 12 candidates could offset revenue losses if half succeed.
View source ↗ - Newszacks.com·59d ago·Neutral
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.
View source ↗ - Newsbusinesswire.com·59d ago·Neutral
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts. Investors and the…
View source ↗ - Newszacks.com·65d ago·Positive
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day.
View source ↗ - News (RSS)seekingalpha·65d ago·Negative
Zoetis: The Worst May Be Priced In
View source ↗ - Newsseekingalpha.com·65d ago·Negative
Zoetis: The Worst May Be Priced In Zoetis faces ongoing headwinds but is now considered a cautious 'Buy' as valuation reflects low-to-mid single-digit growth potential. Q2 results disappointed, with flat revenues and declining U.S. sales, but international and livestock segments showed resilience and growth. Management revised 2026 guidance downward, but ZTS's low valuation multiples and aggressive share buybacks support its fair value case.
View source ↗ - Newsmarketbeat.com·65d ago·Negative
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales Zoetis NYSE: ZTS executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides.
View source ↗ - News (RSS)seekingalpha·66d ago·Positive
Zoetis: An Undervalued Compounder Hiding In Plain Sight
View source ↗ - News (RSS)seekingalpha·66d ago·Neutral
Zoetis: New Competition Changes The Story, But Not Yet The Rating
View source ↗ - News (Marketaux)seekingalpha.com·66d ago·Neutral
Zoetis Stock: New Competition Changes The Story, But Not Yet The Rating (NYSE:ZTS) Zoetis ( ZTS ) still remains on[+181 characters]
View source ↗ - Newsseekingalpha.com·66d ago·Positive
Zoetis: An Undervalued Compounder Hiding In Plain Sight Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my DCF valuation. ZTS faces near-term pressure from weaker U.S. companion animal demand, increased competition, and margin compression due to promotions and rebates. Long-term growth is supported by structural pet humanization trends, international expansion, a robust R&D pipeline, and a growing diagnostics segment.
View source ↗ - News (Marketaux)gurufocus.com·68d ago·Positive
Zoetis Inc at Morgan Stanley Global Healthcare Conference Transcript We're happy to have Zoetis with[+212 characters]
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)yahoo·75d ago·Neutral
Zoetis (ZTS) Shares Drop After Earnings Revision
View source ↗ - Newsbusinesswire.com·81d ago·Neutral
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET. Interested parties can access the live audio webcast …
View source ↗ - News (RSS)seekingalpha·84d ago·Neutral
Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead
View source ↗ - Newsseekingalpha.com·84d ago·Neutral
Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead Phibro Animal Health's Zoetis MFA acquisition has created a larger animal health platform with stronger earnings and broader manufacturing reach. Vaccines, nutritional specialties, and companion-animal expansion give PAHC newer growth verticals beyond the legacy MFA franchise. Management's optimization program and Chicago Heights consolidation could improve efficiency as the acquired portfolio moves beyond integration.
View source ↗ - News (Marketaux)gurufocus.com·86d ago·Positive
A Look at Zoetis Inc (ZTS) After 3.2% Decline -- GF Value $180.60 vs Price $75.02 On August 27, 2026, Zoetis [+256 characters]
View source ↗ - News (RSS)yahoo·90d ago·Neutral
Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
View source ↗ - News (RSS)yahoo·91d ago·Neutral
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
View source ↗ - Newsseekingalpha.com·96d ago·Neutral
Zoetis: A Solid Long-Term Buy After Harsh Drawdown Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic traffic and heightened competition across key companion animal franchises. Despite aggressive competitor promotions, Zoetis protects industry-leading profitability (35%–37% EBIT margins) using targeted gross-to-net rebates rather than base list-price cuts. Trading at a historic low 12x P/E and a 7%+ FCF yield, Zoetis offers a strong margin of safety…
View source ↗ - News (RSS)seekingalpha·98d ago·Neutral
Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap
View source ↗ - Newsseekingalpha.com·98d ago·Neutral
Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap Zoetis' Q2 earnings results were mixed, and the company cut its forward guidance. This has reduced the stock's margin of safety, but on balance, the risk/reward profile still favors the bulls. Zoetis has other segments performing well which partially offset the weakness in U.S. pet-related sales.
View source ↗ - 4chan /biz/biz·100d ago·Neutral
…rns-calculator https://brokerchooser.com/ https://www.chathamfinancial.com/technology/us-market-rates https://iran.liveuamap.com/ >Featured stock of the thread NYSE:ZTS Zoetis Inc >Preivous >>62594031
View source ↗ - 4chan /biz/biz·100d ago·Neutral
…rns-calculator https://brokerchooser.com/ https://www.chathamfinancial.com/technology/us-market-rates https://iran.liveuamap.com/ >Featured stock of the thread NYSE:ZTS Zoetis Inc >Preivous >>62594031
View source ↗ - Newsseekingalpha.com·100d ago·Neutral
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite …
View source ↗ - News (RSS)yahoo·100d ago·Neutral
Zoetis (ZTS) Remains a Leader, So Why Was It Sold?
View source ↗ - News (RSS)investing·101d ago·Neutral
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
View source ↗ - Newsreuters.com·101d ago·Negative
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs The U.S. Food and Drug Administration on Thursday issued an emergency use authorization for Zoetis' flea and tick drug to treat New World screwworm (NWS) infestations in dogs and puppies.
View source ↗ - 4chan /biz/biz·101d ago·Neutral
>>62590170 *ZTS >>62590187 still its a pretty brutal pull back
View source ↗ - News (Marketaux)finance.yahoo.com·105d ago·Positive
Zoetis Q2 Earnings Call Highlights Zoetis lowered its full-year ou[+113 characters]
View source ↗ - Newsmarketbeat.com·105d ago·Neutral
Zoetis Q2 Earnings Call Highlights Zoetis NYSE: ZTS reported second-quarter revenue of $2.5 billion, flat on a reported basis and down 1% organically, as pressure in U.S. companion-animal categories offset growth in livestock, diagnostics and international markets. Adjusted net income was $781 million, down 2% organically, while adjusted diluted earnings per share rose 4% to $1.87, benefiting from a lower share count following share repurchases.
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $1.22 per share
Typical surprise +5.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$1.75 vs $1.51beat
- Thu, Aug 6$1.87 vs $1.85beat
- Thu, May 7$1.53 vs $1.60miss
- Thu, Feb 12$1.48 vs $1.40beat
- Tue, Nov 4$1.70 vs $1.62beat
- Tue, Aug 5$1.76 vs $1.62beat
Estimates and results for ZTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZTS officers and directors.
- Bought
- $886k
- Sold
- —
3 trades
0 trades
- Damelio Frank Abought
- Bisaro Paulbought
- Mccallister Michael Bbought
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Byron Donaldshouse · FL19 · disclosed Nov 16, 2026 (45d later)Sell$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Nov 16, 2026 (45d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (27d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Sell$1,001 - $15,000
- Shelley Moore Capitosenate · WV · disclosed Nov 4, 2026 (14d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 12, 2026 (24d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (14d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Sep 7, 2026 (52d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (36d later)Buy$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Jul 16, 2026 (37d later)Buy$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Jul 16, 2026 (37d later)Buy$1,001 - $15,000
- Chuck Fleischmannhouse · TN03 · disclosed Jul 13, 2026 (34d later)Buy$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Jul 3, 2026 (17d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 11, 2026 (41d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed May 11, 2026 (27d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (26d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2026 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (28d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
